{"id":"W2134009713","doi":"10.1136/annrheumdis-2013-204231","title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":468,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"UCB Pharma; Genentech; Ablynx; Celgene; Biogen; National Center for Advancing Translational Sciences; Chugai Pharmaceutical; Celltrion; Synarc; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Certolizumab pegol; Ankylosing spondylitis; BASDAI; Placebo; BASFI; Axial spondyloarthritis; Internal medicine; Clinical endpoint; Adverse effect; Spondylitis; Physical therapy; Randomized controlled trial; Arthritis; Etanercept; Sacroiliitis; Rheumatoid arthritis; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004087588,0.001892883,0.004009265,0.0004991926,0.0007104012,0.001314102,0.001255955,0.003274391,0.004908479],"category_scores_gemma":[0.002424589,0.0009934878,0.002897548,0.0004786311,0.001634905,0.001391189,0.0004753275,0.003162173,0.001235863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007473454,"about_ca_system_score_gemma":0.0013773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007492179,"about_ca_topic_score_gemma":0.001256535,"domain_scores_codex":[0.9985945,0.0007831477,0.0001043243,0.0002038588,0.0001320845,0.0001820646],"domain_scores_gemma":[0.9979625,0.0004997843,0.0005325273,0.0001984681,0.0001890182,0.0006177599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9675044,0.01276433,0.000620132,0.0004841144,0.0007357507,0.0000526887,0.00006618899,0.0002084568,0.004922618,0.00002419141,0.0004154303,0.01220164],"study_design_scores_gemma":[0.8710627,0.1247094,0.003063976,0.00001973838,0.000272304,0.00003825633,0.00001321275,0.0001553819,0.0003759265,0.00004419781,0.0002308311,0.00001416604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884128,0.003956364,0.0007294262,0.0004335881,0.000264467,0.004135161,0.001045291,0.0001341563,0.0008887026],"genre_scores_gemma":[0.9879335,0.00209784,0.001333188,0.0009913059,0.0004205555,0.004149218,0.001234742,0.00003899127,0.001800849],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004908479,"threshold_uncertainty_score":0.02161747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0739254593812622,"score_gpt":0.3478465486476314,"score_spread":0.2739210892663692,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}